Key facts
- MORF Bio’s last known valuation is $2.6M (Sep 2025).
- It has raised $430K; the latest was Seed Round ($430K) in Sep 2025.
- Notable investors include Deeptech Seed Fund, ICURe, University of York, York Angel Investors.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for MORF Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for MORF Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MORF Bio
Developer of a visual bioinformatics platform designed to simplify complex biological data analysis and accelerate biotech innovation. The company offers a no-code, web-based platform for multi-omics and bioprocess data analysis, enabling customers to validate engineered strains, interpret microbial bioinformatics and collaborate seamlessly across teams, driving faster, more transparent and scalable biotech R&D outcomes.
- Sector
- Information Technology
- HQ
- York, United Kingdom
- Founded
- 2025
- Employees
- 8
- Website
- morf-bio.com/
- Ownership
- Privately Held (backing)
MORF Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MORF Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MORF Bio in its N-PORT filings yet. We sweep new filings monthly.